Trial suggests that treatment de-escalation in HER2-positive breast cancer needs to be personalized

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

De-escalation approaches in the treatment of women with HER2-positive breast cancer need to be personalized, according to Carmen Criscitiello at the European Institute of Oncology. Her comments will be included in a presentation of updated research results at the inaugural ESMO Breast Cancer Congress 2019, May 2-4, in Berlin.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login